# Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

> **NCT05042934** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Metastatic Ewing Sarcoma
- Recurrent Ewing Sarcoma

## Interventions

- **PROCEDURE:** Fine-Needle Aspiration
- **DRUG:** Irinotecan
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT05042934
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-15
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI stated trial no longer fits the framework \& portfolio of work that is prioritized by the department. PI will not have the anticipated accrual in PI view to complete the study. Given that, PI request this protocol be closed prior to its activation.
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042934, "Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05042934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*